NJIPLA to Host the 27th Annual Pharmaceutical / Chemical Patent Practice Update

On Wednesday, December 11, the New Jersey Intellectual Property Association will host the 27th Annual Pharmaceutical / Chemical Patent Practice Update at the Woodbridge Hilton in Iselin, NJ. This seminar will cover a range of important topics pertaining to arising pharmaceutical patent matters such as:

  • Impact of Erosion of IP Rights on the Pharmaceutical Industry
  • Maximizing the Probability of Success in Post-Grant Proceedings for Pharmaceutical Patents
  • Patent Term Adjustment Strategies
  • The Bolar Exemption in the EU and UK
  • Claiming Functionally-Defined Biologics
  • “Self-Colliding” Co-Pending Applications at the EPO
  • Recent Developments in Hatch-Waxman Litigation: (1) Impact of FTC v. Actavis on Pharmaceutical Patent Settlements; and (2) NCE Exclusivity for Enantiomers and Combination Products
  • USPTO Ethics Horror Stories – Tales from the OED Crypt

Robert E. Rudnick, the President of the NJIPLA and a Director in the Gibbons Intellectual Property Department, will kick-off the seminar by introducing the program and its speakers. Various professionals within the intellectual property field will tap into their own experience, in order to provide insight and knowledge on these issues. For more information or to register, please click here.

Print